Pesquisar
Spero Therapeutics Inc
SPROAdicionar à lista de desejos
1.265USD
+0.005+0.40%
Horário de mercado 09/24, 10:34（ET）
73.24MValor de mercado
4.56P/L TTM
Sobre o Spero Therapeutics Inc Empresa
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc Perfil
Código da empresaSPRO
Nome da EmpresaSpero Therapeutics Inc
Data de listagemNov 02, 2017
CEORajavelu (Esther)
Número de funcionários32
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 02
Endereço675 Massachusetts Ave Ste 14
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02139-3309
Telefone18572421600
Sitehttps://sperotherapeutics.com/
Código da empresaSPRO
Data de listagemNov 02, 2017
CEORajavelu (Esther)
Executivos da empresa Spero Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
81.45K
+12.28%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
81.45K
+12.28%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
81.45K
+12.28%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Perguntas frequentes
Quem são os cinco principais acionistas de Spero Therapeutics Inc?
Os cinco principais acionistas de Spero Therapeutics Inc são: Dr. Ankit Mahadevia, M.D.
Quantas instituições possuem ações da Spero Therapeutics Inc (SPRO)?
Em 2026Q1, 117 instituições possuíam ações da Spero Therapeutics Inc, com valor de mercado aproximado de 11.81M, representando 20.40% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1291189.00.